Trends over time in Escherichia coli bloodstream infections, urinary tract infections, and antibiotic susceptibilities in Oxfordshire, UK, 1998–2016: a study of electronic health records

The Lancet Infectious Diseases

Volumn 18, Issue 10, 2018, Pages 1138-1149

  Vihta, Karina Doris ^a,c   Stoesser, Nicole ^a   Llewelyn, Martin J ^d   Quan, T Phuong ^a,c   Davies, Tim ^a,c   Fawcett, Nicola J ^a   Dunn, Laura ^e   Jeffery, Katie ^e   Butler, Chris C ^b   Hayward, Gail ^b   Andersson, Monique ^e   Morgan, Marcus ^e   Oakley, Sarah ^e   Mason, Amy ^a   Hopkins, Susan ^f   Wyllie, David H ^a   Crook, Derrick W ^a,c,f   Wilcox, Mark H ^g   Johnson, Alan P ^c,f   Peto, Tim E A ^a,c   Walker, A Sarah ^a,c   more..

^a UNIVERSITY OF OXFORD   (United Kingdom)

^b UNIVERSITY OF OXFORD   (United Kingdom)

^c The National Institute for Health Research Health Protection Research Unit in Blood Borne and Sexually Transmitted Infections at University College London in partnership with UK Health Security Agency   (United Kingdom)

^d UNIVERSITY OF SUSSEX   (United Kingdom)

^e OXFORD UNIVERSITY HOSPITALS NHS FOUNDATION TRUST   (United Kingdom)

^f PUBLIC HEALTH ENGLAND   (United Kingdom)

^g UNIVERSITY OF LEEDS   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

AMOXICILLIN; AMOXICILLIN PLUS CLAVULANIC ACID; C REACTIVE PROTEIN; CEFALEXIN; CEFTAZIDIME; CEFTRIAXONE; CIPROFLOXACIN; GENTAMICIN; MEROPENEM; NITROFURANTOIN; PIPERACILLIN PLUS TAZOBACTAM; TRIMETHOPRIM; ANTIINFECTIVE AGENT;

ALL CAUSE MORTALITY; ANTIBIOTIC RESISTANCE; ARTICLE; BACTERIAL VIRULENCE; BLOOD CULTURE; BLOODSTREAM INFECTION; CONTROLLED STUDY; ELECTRONIC HEALTH RECORD; ESCHERICHIA COLI; GASTROINTESTINAL DISEASE; HOSPITAL ADMISSION; HUMAN; INCIDENCE; MAJOR CLINICAL STUDY; MORTALITY; NEUTROPHIL; OBSERVATIONAL STUDY; OCCUPATIONAL EXPOSURE; PRIMARY MEDICAL CARE; PRIORITY JOURNAL; TREATMENT OUTCOME; UNITED KINGDOM; URINARY TRACT INFECTION; URINE CULTURE; URINE SAMPLING; BACTEREMIA; ESCHERICHIA COLI INFECTION; TIME FACTOR;

AMOXICILLIN-POTASSIUM CLAVULANATE COMBINATION; ANTI-BACTERIAL AGENTS; BACTEREMIA; DRUG RESISTANCE, BACTERIAL; ELECTRONIC HEALTH RECORDS; ESCHERICHIA COLI INFECTIONS; HUMANS; INCIDENCE; TIME FACTORS; URINARY TRACT INFECTIONS;

EID: 85054777365     PISSN: 14733099     EISSN: 14744457     Source Type: Journal    
DOI: 10.1016/S1473-3099(18)30353-0     Document Type: Article

References (43)

1. Public Health England. Polymicrobial bacteraemia and fungaemia in England, Wales and Northern Ireland, 2014. Public Health England. https://assets.publishing.service.gov.uk/government/uploads/system/uploads/attachment_data/file/436558/hpr2115_plmcrbls.pdf, June, 2015. (Accessed 19 June 2018)
2. Review on Antimicrobial Resistance. Antimicrobial resistance: tackling a crisis for the health and wealth of nations. 2014, UK Government and Wellcome Trust, London.
3. Buetti, N, Atkinson, A, Marschall, J, Kronenberg, A, Incidence of bloodstream infections: a nationwide surveillance of acute care hospitals in Switzerland 2008–2014. BMJ Open, 7, 2017, e013665.
4. European Centre for Disease Prevention and Control. Surveillance of antimicrobial resistance in Europe. 2016, European Centre for Disease Prevention and Control, Stockholm https://ecdc.europa.eu/sites/portal/files/documents/AMR-surveillance-Europe-2016.pdf, 2016. (Accessed 19 June 2018)
5. van der Mee-Marquet, NL, Blanc, DS, Gbaguidi-Haore, H, et al. Marked increase in incidence for bloodstream infections due to Escherichia coli, a side effect of previous antibiotic therapy in the elderly. Front Microbiol, 6, 2015, 646.
6. Public Health England. Annual epidemiological commentary: mandatory MRSA, MSSA and E. coli bacteraemia and C. difficile infection data, 2014/15. 2015, Public Health England, London.
7. Public Health England. Annual epidemiological commentary: mandatory MRSA, MSSA and E. coli bacteraemia and C. difficile infection data, 2015/16. 2016, Public Health England, London.
8. Laupland, KB, Gregson, DB, Church, DL, Ross, T, Pitout, JD, Incidence, risk factors and outcomes of Escherichia coli bloodstream infections in a large Canadian region. Clin Microbiol Infect 14 (2008), 1041–1047.
9. Schlackow, I, Stoesser, N, Walker, AS, Crook, DW, Peto, TE, Wyllie, DH, Increasing incidence of Escherichia coli bacteraemia is driven by an increase in antibiotic-resistant isolates: electronic database study in Oxfordshire 1999–2011. J Antimicrob Chemother 67 (2012), 1514–1524.
10. Abernethy, J, Guy, R, Sheridan, EA, et al. Epidemiology of Escherichia coli bacteraemia in England: results of an enhanced sentinel surveillance programme. J Hosp Infect 95 (2017), 365–375.
11. Public Health England. Thirty-day all-cause fatality subsequent to MRSA, MSSA and E. coli bacteraemia and C. difficile infection, 2014/15. 2015, Public Health England, London.
12. Livermore, DM, Stephens, P, Weinberg, J, et al. Regional variation in ampicillin and trimethoprim resistance in Escherichia coli in England from 1990 to 1997, in relation to antibacterial prescribing. J Antimicrob Chemother 46 (2000), 411–422.
13. Hay, AD, Thomas, M, Montgomery, A, et al. The relationship between primary care antibiotic prescribing and bacterial resistance in adults in the community: a controlled observational study using individual patient data. J Antimicrob Chemother 56 (2005), 146–153.
14. Kahlmeter, G, Menday, P, Cars, O, Non-hospital antimicrobial usage and resistance in community-acquired Escherichia coli urinary tract infection. J Antimicrob Chemother 52 (2003), 1005–1010.
15. Livermore, DM, Hope, R, Reynolds, R, Blackburn, R, Johnson, AP, Woodford, N, Declining cephalosporin and fluoroquinolone non-susceptibility among bloodstream Enterobacteriaceae from the UK: links to prescribing change?. J Antimicrob Chemother 68 (2013), 2667–2674.
16. Lishman H, Costelloe C, Hopkins S, et al. Effect of trimethoprim/nitrofurantoin prescribing on the incidence and antibiotic susceptibility patterns of E. coli bacteraemia nationally at the GP practice level (2012–2014). 26th European Congress of Clinical Microbiology and Infectious Diseases; Amsterdam; April 9–12, 2016. EP0072.
17. Ironmonger, D, Edeghere, O, Verlander, NQ, et al. Effect of general practice characteristics and antibiotic prescribing on Escherichia coli antibiotic non-susceptibility in the West Midlands region of England: a 4 year ecological study. J Antimicrob Chemother 73 (2018), 787–794.
18. Ho, PL, Chow, KH, Lai, EL, Lau, EH, Cheng, VC, Extended-spectrum-β-lactamase-positive Escherichia coli mainly adds to, rather than replaces, extended-spectrum-β-lactamase-negative E. coli in causing bacteraemia in Hong Kong, 2000–10. J Antimicrob Chemother 67 (2012), 778–780.
19. Llewelyn, MJ, Hand, K, Hopkins, S, Walker, AS, Antibiotic policies in acute English NHS trusts: implementation of “start smart-then focus” and relationship with Clostridium difficile infection rates. J Antimicrob Chemother 70 (2015), 1230–1235.
20. Public Health England. English surveillance programme for antimicrobial utilisation and resistance (ESPAUR). Report 2017. 2017, Public Health England, London.
21. Finney, JM, Walker, AS, Peto, TE, Wyllie, DH, An efficient record linkage scheme using graphical analysis for identifier error detection. BMC Med Inform Decis Mak, 11, 2011, 7.
22. Public Health England. Mandatory enhanced MRSA, MSSA and Escherichia coli bacteraemia, and Clostridium difficile infection surveillance, 2015/16. 2016, Public Health England, London.
23. Butler, C, Dunstan, F, Heginbothom, M, et al. Containing antibiotic resistance: decreased antibiotic-resistant coliform urinary tract infections with reduction in antibiotic prescribing by general practices. Br J Gen Pract 57 (2007), 785–792.
24. Garner, JS, Jarvis, WR, Emori, TG, Horan, TC, Hughes, JM, CDC definitions for nosocomial infections, 1988. Am J Infect Control 16 (1988), 128–140.
25. Wyllie, DH, Walker, AS, Peto, TE, Crook, DW, Hospital exposure in a UK population, and its association with bacteraemia. J Hosp Infect 67 (2007), 301–307.
26. NHS Improvement and Public Health England. Guidance on the definition of healthcare associated Gram-negative bloodstream infections. July, 2017, NHS Improvement and Public Heath England.
27. Cardoso, T, Almeida, M, Friedman, ND, et al. Classification of healthcare-associated infection: a systematic review 10 years after the first proposal. BMC Med, 12, 2014, 40.
28. Office for National Statistics. Dataset: clinical commissioning group mid year population estimates (national statistics). 2018, Office for National Statistics https://www.ons.gov.uk/peoplepopulationandcommunity/populationandmigration/populationestimates/datasets/clinicalcommissioninggroupmidyearpopulationestimates. (Accessed 17 March 2018)
29. Schlackow, I, Walker, SA, Dingle, K, et al. Surveillance of infection severity: a registry study of laboratory diagnosed Clostridium difficile. PLoS Med, 9, 2012, e1001279.
30. Lunn, M, McNeil, D, Applying Cox regression to competing risks. Biometrics 51 (1995), 524–532.
31. Hillier, S, Roberts, Z, Dunstan, F, Butler, C, Howard, A, Palmer, S, Prior antibiotics and risk of antibiotic-resistant community-acquired urinary tract infection: a case-control study. J Antimicrob Chemother 60 (2007), 92–99.
32. Butler, CC, Francis, N, Thomas-Jones, E, et al. Variations in presentation, management, and patient outcomes of urinary tract infection: a prospective four-country primary care observational cohort study. Br J Gen Pract 67 (2017), e830–e841.
33. Gágyor, I, Bleidorn, J, Kochen, MM, Schmiemann, G, Wegscheider, K, Hummers-Pradier, E, Ibuprofen versus fosfomycin for uncomplicated urinary tract infection in women: randomised controlled trial. BMJ, 351, 2015, h6544.
34. Ashiru-Oredope, D, Sharland, M, Charani, E, McNulty, C, Cooke, J, Improving the quality of antibiotic prescribing in the NHS by developing a new antimicrobial stewardship programme: Start Smart—Then Focus. J Antimicrob Chemother 67:suppl 1 (2012), i51–i63.
35. Wyllie, DH, Walker, AS, Miller, R, et al. Decline of meticillin-resistant Staphylococcus aureus in Oxfordshire hospitals is strain-specific and preceded infection-control intensification. BMJ Open, 1, 2011, e000160.
36. Duerden, B, Fry, C, Johnson, AP, Wilcox, MH, The control of methicillin-resistant Staphylococcus aureus blood stream infections in England. Open Forum Infect Dis, 2, 2015, ofv035.
37. Goto, M, O'Shea, AMJ, Livorsi, DJ, et al. The effect of a nationwide infection control program expansion on hospital-onset Gram-negative rod bacteremia in 130 veterans health administration medical centers: an interrupted time-series analysis. Clin Infect Dis 63 (2016), 642–650.
38. Díez-Aguilar, M, Morosini, MI, López-Cerero, L, et al. Performance of EUCAST and CLSI approaches for co-amoxiclav susceptibility testing conditions for clinical categorization of a collection of Escherichia coli isolates with characterized resistance phenotypes. J Antimicrob Chemother 70 (2015), 2306–2310.
39. Leverstein-van Hall, MA, Waar, K, Muilwijk, J, Cohen Stuart, J, Consequences of switching from a fixed 2:1 ratio of amoxicillin/clavulanate (CLSI) to a fixed concentration of clavulanate (EUCAST) for susceptibility testing of Escherichia coli. J Antimicrob Chemother 68 (2013), 2636–2640.
40. Davies T, Stoesser N, Abuoun M, et al. Significant discordance in amoxicillin-clavulanate phenotyping methods and genotypic attribution of phenotypic “resistance” for clinical Escherichia coli isolates. 27th European Congress of Clinical Microbiology and Infectious Diseases. Vienna; April 22–25, 2017. P0151.
41. Fitzpatrick, JM, Biswas, JS, Edgeworth, JD, et al. Gram-negative bacteraemia; a multi-centre prospective evaluation of empiric antibiotic therapy and outcome in English acute hospitals. Clin Microbiol Infect 22 (2016), 244–251.
42. European Committee on Antimicrobial Susceptibility Testing. MIC distributions and ECOFFs. European Committee on Antimicrobial Susceptibility Testing. http://www.eucast.org/mic_distributions_and_ecoffs/. (Accessed 16 December 2016)
43. Kallonen, T, Brodrick, HJ, Harris, SR, et al. Systematic longitudinal survey of invasive Escherichia coli in England demonstrates a stable population structure only transiently disturbed by the emergence of ST131. Genome Res 27 (2017), 1437–1449.